When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP)

Drug Discovery Today: Therapeutic Strategies

Volumn 5, Issue 4, 2008, Pages 255-262

  Kaplan, Frederick S ^a   Groppe, Jay ^b   Shore, Eileen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR IA; ACTIVIN RECEPTOR LIKE KINASE 2; BONE MORPHOGENETIC PROTEIN; DORSOMORPHIN; MONOCLONAL ANTIBODY; NOGGIN; SIGNAL TRANSDUCTION INHIBITOR; SMALL INTERFERING RNA; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG;

BONE DEVELOPMENT; CLINICAL FEATURE; DIAGNOSTIC ERROR; DRUG SCREENING; ENVIRONMENTAL FACTOR; FEMUR MALFORMATION; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FIBROUS DYSPLASIA; GENE MAPPING; HEREDITY; HETEROTOPIC OSSIFICATION; HUMAN; HYPOXIC CELL; INFLAMMATORY CELL; METAGENOMICS; MISSENSE MUTATION; NONHUMAN; PATHOGENESIS; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SPINE MALFORMATION; STROMA CELL; THUMB MALFORMATION; TOE MALFORMATION;

EID: 71649100825     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2008.11.004     Document Type: Review

References (65)

1. Kaplan F.S., et al. The phenotype of fibrodysplasia ossificans progressiva. Clin. Rev. Bone Miner. Metab. 3 (2005) 183-188
2. Kaplan F.S., et al. Fibrodysplasia ossificans progressiva. Best Pract. Res. Clin. Rheumatol. 22 (2008) 191-205
3. Shore E.M., et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 38 (2006) 525-527
4. Cohen R.B., et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. J. Bone Joint Surg. 75-A (1993) 215-219
5. Rocke D.M., et al. Age and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 301 (1994) 243-248
6. Kaplan F.S., and Zasloff M.A. The histopathology of fibrodysplasia ossificans progressiva: an endochondral process. J. Bone Joint Surg. 75-A (1993) 220-230
7. Pignolo R.J., et al. The fibrodysplasia ossificans progressiva lesion. Clin. Rev. Bone Miner. Metab. 3 (2005) 195-200
8. Glaser D.L., et al. Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 346 (1998) 110-116
9. Janoff H.B., et al. Submandibular swelling in patients with fibrodysplasia ossificans progressiva. Otolaryngol. Head Neck Surg. 114 (1996) 599-604
10. Lanchoney T.F., et al. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J. Pediatr. 126 (1995) 762-764
11. Luchetti W., et al. Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 81 (1995) 21-25
12. Moriatis J.M., et al. Limb swelling in patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 336 (1997) 247-253
13. Scarlett R.F., et al. Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva (FOP). Clin. Orthop. Rel. Res. 423 (2004) 275-279
14. Shah P.B., et al. Spinal deformity in patients who have fibrodysplasia ossificans progressiva. J. Bone Joint Surg. 76-A (1994) 1442-1450
15. Kussmaul W.G., et al. Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 346 (1998) 104-109
16. Kaplan F.S., and Glaser D.L. Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. Clin. Rev. Bone Miner. Metab. 3 (2005) 213-216
17. Shore E.M., et al. The genetics of fibrodysplasia ossificans progressiva. Clin. Rev. Bone Miner. Metab. 3 (2005) 201-204
18. Kitterman J.A., et al. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 116 (2005) 654-661
19. Kaplan F.S., et al. Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 121 (2008) e1295-e1300
20. Schaffer A., et al. Developmental anomalies of the cervical spine in patients with fibrodysplasia ossificans progressiva are distinctly different from those in patients with Klippel-Feil syndrome. Spine 30 (2005) 1379-1385
21. Deirmengian G.K., et al. Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva. J. Bone Joint Surg. Am. 90 (2008) 366-374
22. Hebela N., et al. Three pairs of monozygotic twins with fibrodysplasia ossificans progressiva: the role of environment in the progression of heterotopic ossification. Clin. Rev. Bone Miner. Metab. 3 (2005) 205-208
23. Kaplan F.S., et al. Fibrodysplasia ossificans progressiva: a clue from the fly?. Calcif. Tissue Int. 47 (1990) 117-125
24. Ahn J., et al. Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J. Bone Joint Surg. 85-A (2003) 667-674
25. Billings P.C., et al. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva. J. Bone Miner. Res. 23 (2008) 305-313
26. Fiori J.L., et al. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J. Bone Miner. Res. 21 (2006) 902-909
27. Gannon F.H., et al. Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum. Pathol. 28 (1997) 339-343
28. Kan L., et al. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am. J. Pathol. 165 (2004) 1107-1115
29. Kaplan F.S., et al. Dysregulation of BMP4 receptor trafficking and signaling in fibrodysplasia ossificans progressiva. Clin. Rev. Bone Miner. Metab. 3 (2005) 217-223
30. Kaplan F.S., et al. Dysregulation of the BMP4 signaling pathway in fibrodysplasia ossificans progressiva. Ann. N. Y. Acad. Sci. 1068 (2006) 54-65
31. Olmsted E.A., et al. Bone morphogenetic protein 4 regulation in fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 408 (2003) 331-343
32. Serrano de la Peña L., et al. Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J. Bone Miner. Res. 20 (2005) 1168-1176
33. Shafritz A.B., et al. Over-expression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N. Engl. J. Med. 335 (1996) 555-561
34. Kaplan F.S., and Shore E.M. Morphogen receptor genes and metamorphogenes: skeleton keys to metamorphosis. Ann. N. Y. Acad. Sci. 1116 (2007) 113-133
35. Gannon F.H., et al. Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 346 (1998) 19-25
36. Kaplan F.S., et al. Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 304 (1994) 238-247
37. Mahboubi S., et al. Fibrodysplasia ossificans progressiva. Pediatr. Radiol. 31 (2001) 307-314
38. Jiao X., et al. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J. Biol. Chem. 282 (2007) 1080-1086
39. Kaplan F.S., et al. A new era of fibrodysplasia ossificans progressiva (FOP): a druggable target for the second skeleton. Exp. Opin. Biol. Ther. 7 (2004) 705-712
40. Zhang D., et al. ALK2 functions as a type I BMP receptor and induces Indian Hedgehog in chondrocytes during skeletal development. J. Bone Miner. Res. 18 (2003) 1593-1604
41. Shen Q., et al. Activation of BMP signaling by the FOP ACVR1 R206H mutation. J. Bone Miner. Res. 22 Suppl. 1 (2007) S43
42. Fukuda, T. et al. Constitutively activated ALK2 and increased smad 1/5 cooperatively induce BMP signaling in fibrodysplasia ossificans progressiva. J. Biol. Chem. 2008 Aug 6 (Epub ahead of print)
43. Groppe J.C., et al. Functional modeling of the ACVR1 (R206H) mutation in FOP. Clin. Orthop. Rel. Res. 462 (2007) 87-92
44. Chen Y.-G., et al. Mechanism of TGF-β receptor inhibition by FKBP12. EMBO J. 16 (1997) 3866-3876
45. Ebisawa T., et al. Smurf 1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276 (2001) 12477-12480
46. Huse M., et al. Crystal structure of the cytosplasmic domain of the type I TGF-β receptor in complex with FKBP12. Cell 96 (1999) 425-436
47. Huse M., et al. The TGF-β receptor activation process: an inhibitor-to-substrate binding switch. Mol. Cell 8 (2001) 671-682
48. Wang T., et al. The immunophilin FKBP12 functions as a common inhibitor of the TGF-β family type I receptors. Cell 86 (1996) 435-444
49. Yamaguchi T., et al. FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin type I receptor. J. Mol. Endocrinol. 36 (2006) 569-579
50. Kaplan F.S. Fibrodysplasia ossificans progressiva: an historical perspective. Clin. Rev. Bone Miner. Metab. 3 (2005) 179-181
51. Rosenstirn J.A. A contribution to the study of myositis ossificans progressiva. Ann. Surg. 68 (1918) 468-520 591-637
52. Fishman M.C., and Porter J.A. A new grammar for drug discovery. Nature 437 (2005) 491-493
53. Kaplan F.S. The key to the closet is the key to the kingdom: a common lesson of rare diseases. Orphan Dis. Update 24 (2006) 1-9
54. Yu P.B., et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 4 (2008) 33-41
55. Anderson G.J., and Darshan D. Small-molecule dissection of BMP signaling. Nat. Chem. Biol. 4 (2008) 15-16
56. Yu P.B., et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat. Med. 14 (2008) 1363-1369
57. Glaser D.L., et al. In vivo somatic cell gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification. J. Bone Joint Surg. 85-A (2003) 2332-2342
58. Hegyi L., et al. Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification. J. Pathol. 201 (2003) 141-148
59. Kaplan F.S., et al. Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 pathway. Clin. Rev. Bone Miner. Metab. 3 (2005) 189-193
60. Kaplan F.S., et al. Hematopoietic stem-cell contribution to ectopic skeletogenesis. J. Bone Joint Surg. Am. 89 (2007) 347-357
61. Kaplan F.S., et al. Heterotopic ossification. J. Am. Acad. Orthop. Surg. 12 (2004) 116-125
62. Lounev, V. et al. Identification of progenitor cells that contribute to heterotopic skeletogenesis. J. Bone Joint Surg. Am. (in press)
63. Chakkalakal S.A., et al. ACVR1 knock-in mouse model for fibrodysplasia ossificans progressiva. J. Bone Miner. Res. 23 Suppl. 1 (2008) S57
64. Olmsted-Davis E., et al. Hypoxic adipocytes pattern early heterotopic bone formation. Am. J. Pathol. 170 (2007) 620-632
65. Roush W. Protein builds second skeleton. Science 273 (1996) 1170